MFG
SRPT icon

Merit Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

Merit Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$296K Sell
16,487
-12,261
-43% -$232K ﹤0.01% 1822
2026
Q1 		$626K Sell
28,748
-9,375
-25% -$181K ﹤0.01% 1235
2025
Q4 		$820K Buy
+38,123
New +$803K 0.01% 1032

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Merit Financial Group's SRPT Position: Q2 2026 in Review

Merit Financial Group reduced its Sarepta Therapeutics (SRPT) stake by 43% in Q2 2026, selling an estimated $232K and leaving 16,487 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #1822.

Merit Financial Group first reported a position in SRPT in Q4 2025 and has held it in 3 quarters since. The position peaked at $820K in Q4 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Merit Financial Group held 16,487 shares of Sarepta Therapeutics worth $296K as of Q2 2026.
  • Merit Financial Group sold 12,261 Sarepta Therapeutics shares in Q2 2026, an estimated $232K.
  • Sarepta Therapeutics made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #1822 holding.
  • Merit Financial Group first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Merit Financial Group's Sarepta Therapeutics position peaked at $820K in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.